📰 Loncode Institute News
Page 4 - Loncode Institute News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Loncode Institute. Real-time updates on events, politics, business and more.
May 18, 2022
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. "The
May 3, 2022
National public-private consortium aims to bring together researchers, oncologists, knowledge institutes and the business community to collaboratively develop better and affordable cancer medicines more quicklyDURHAM, N.C.--(BUSINESS WIRE)--Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) te...
April 21, 2022
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active
April 21, 2022
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma Active Biotech...
April 19, 2022
LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / -- MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund. Oncode Instit...
April 19, 2022
MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund. Oncode Institute will lead the Oncode-PACT consortium and its ...
April 14, 2022
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that the company will participate
April 14, 2022
Investegate announcements from Immunicum AB, Immunicum AB: Immunicum to Participate in the New Cancer Research Consortium Oncode-PACT
April 14, 2022
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established...
March 25, 2022
The correction refers to the administrative costs for the period January - December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK 15